GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update

* Financial Highlights * Cash and cash equivalents totaled €113.8 million as of June 30, 2026; expected to fund the Company beyond the end of 2028 * €21.1 million in revenues as of June 30, 2026, including €21.0 million in royalties generated under the Ipsen agreement

* Key Highlights * PBC: Ipsen doubled its peak annual global sales target for Iqirvo® in PBC to €1 billion, underscoring the value creation potential of GENFIT's licensing agreement * MASH: Medicare coverage secured in August 2026 in the United States for NASHnext®, the Labcorp-commercialized test based on GENFIT's NIS™ technology; estimated U.S. peak sales of products based on GENFIT’s NIS™ technology could exceed $1.5 billion by 2033 (IQVIA) * ACLF: Clinical-stage pipeline re-focused on the planned initiation of two Phase 2 clinical trials, of nangibotide and nitazoxanide, before year-end * CCA: Continued advancement of GNS561 in combination therapy, including expansion of the Phase 1b study into additional cohorts following encouraging preliminary data; preparation for a Phase 2 trial expected to commence before year-end Lille (France), Cambridge (Massachusetts, United States); September 28, 2026 – GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half 2026 financial results and provided a corporate update.